Eye allergy
diseaseOn this page
Summary
Eye allergy (MONDO:0005551) is a disease and 2 clinical trials. Top therapeutic interventions include olopatadine. A subtype of allergic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 2
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | eye allergy |
| Mondo ID | MONDO:0005551 |
| EFO | EFO:0005751 |
| UMLS | C0852875 |
| MedGen | 1843485 |
| Anatomy (UBERON) | UBERON:0000019 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of allergic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › immune system disorder › hypersensitivity reaction disease › allergic disease › eye allergy
Related subtypes (11): allergic respiratory disease, drug allergy, gastrointestinal allergy, latex allergy, atopic eczema, atopic IgE-mediated allergic disorder, vulvovaginitis, allergic seminal, allergic otitis media, alpha-gal syndrome, venom allergy, food allergy
Subtypes (2): allergic contact dermatitis of eyelid, atopic conjunctivitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
18 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Alcaftadine | Approved (phase 4) |
| Azelastine | Approved (phase 4) |
| Bilastine | Approved (phase 4) |
| Brimonidine | Approved (phase 4) |
| Cetirizine | Approved (phase 4) |
| Cromolyn | Approved (phase 4) |
| Emedastine | Approved (phase 4) |
| Epinastine | Approved (phase 4) |
| Ketotifen | Approved (phase 4) |
| Levocabastine | Approved (phase 4) |
| Lodoxamide | Approved (phase 4) |
| Naphazoline | Approved (phase 4) |
| Nedocromil | Approved (phase 4) |
| Olopatadine | Approved (phase 4) |
| Oxymetazoline | Approved (phase 4) |
| Phenylephrine | Approved (phase 4) |
| Tetrahydrozoline | Approved (phase 4) |
| Xylometazoline | Approved (phase 4) |
Clinical trials & evidence
Clinical trials
Clinical trials: 2.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07404956 | Not specified | RECRUITING | THE EFFECT OF SURGICAL MASK AND N95 MASK USE ON SURGICAL SMOKE IN OPERATING ROOM NURSES |
| NCT01450176 | Not specified | COMPLETED | Comparing Patient Satisfaction With Pataday or Bepreve |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| OLOPATADINE | 4 | 1 |
Related Atlas pages
- Drugs: Olopatadine